Scarica l'app Stockscreener
39.55
2.92%
-1.19
Pre-mercato:
39.55
Precedente Chiudi:
$40.74
Aprire:
$40.36
Volume 24 ore:
187.73K
Relative Volume:
0.53
Capitalizzazione di mercato:
$3.02B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-14.43
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
-1.54%
1M Prestazione:
-5.95%
6M Prestazione:
+0.76%
1 anno Prestazione:
-16.12%
Intervallo 1D:
$39.52
$40.36
Intervallo di 1 settimana:
$39.52
$41.74
Portata 52W:
$35.53
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
39.55 | 3.02B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Trading (XENE) With Integrated Risk Controls - Stock Traders Daily
Dravet Syndrome Thereapeutics Market Size, Future Consumer Behavior and Market Dynamics (2024-2034) - 100×100 Música
Xenon to Showcase Innovations at J.P. Morgan Healthcare Conference - TipRanks
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
JPMorgan Chase & Co. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
JPMorgan Chase & Co. Buys 905,129 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Barclays PLC - MarketBeat
Barclays PLC Has $590,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Buys 32,701 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - Defense World
Stifel Financial Corp Has $849,000 Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Franklin Resources Inc. - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 Shares - MarketBeat
Xenon Pharmaceuticals CFO sells shares worth $770,911 - Investing.com
Xenon Pharmaceuticals CFO sells shares worth $770,911 By Investing.com - Investing.com UK
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1%Here's Why - MarketBeat
BNP Paribas Financial Markets Reduces Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals participates in a conference call with William Blair - Nasdaq
(XENE) Trading Advice - Stock Traders Daily
Citigroup Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - MSN
Lord Abbett & CO. LLC Trims Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook - Investing.com India
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook By Investing.com - Investing.com Australia
Xenon Pharmaceuticals’ (XENE) Buy Rating Reiterated at HC Wainwright - Defense World
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? - MSN
XENE Makes Notable Cross Below Critical Moving Average - Nasdaq
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Buy Rating from HC Wainwright - MarketBeat
Wellington Management Group LLP Buys 15,226 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Two Sigma Advisers LP Buys 64,800 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
(XENE) Technical Data - Stock Traders Daily
Point72 Asset Management L.P. Sells 98,732 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 - The Manila Times
Xenon's Azetukalner Shows Breakthrough Seizure Freedom Data: 33% of Patients Seizure-Free in Long-Term Study - StockTitan
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - The Manila Times
Xenon Pharmaceuticals named a Best Idea for 2025 at TD Cowen - MSN
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Janus Henderson Group PLC - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Erste Asset Management GmbH Acquires New Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
104,960 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Walleye Capital LLC - MarketBeat
Fmr LLC Has $272.35 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is Braidwell LP's 7th Largest Position - MarketBeat
Vestal Point Capital LP Has $32.48 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Investors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Natixis Advisors LLC Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):